The financials
Nektar Therapeutics by the numbers
Nektar Therapeutics (NKTR) reported revenue of $11M in Q1 2026 (quarter ended March 31, 2026), up 3.8% from the same quarter a year earlier. That came with net loss of $45M. For the full year FY2025, revenue was $55M (−44% year on year) and net income −$164M. Its largest product in 2025-Q3 was Non Cash Royalty Revenue Related To Sale Of Future Royalties at $11M, 97% of the disclosed total, just ahead of License Collaboration And Other at 2.5%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $11M | $10M | +3.8% |
| Gross profit | n/a | $10M | n/a |
| Operating income | −$39M | −$45M | n/a |
| Net income | −$45M | −$51M | n/a |
| Diluted EPS | −$1.82 | −$3.62 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Non Cash Royalty Revenue Related To Sale Of Future Royalties | $11M | 97% |
| License Collaboration And Other | $300K | 2.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $10.9M (-7.9%)
Non Cash Royalty Revenue Related To Sale Of Future Royalties grew +3.8% year on year
Segment Latestquarter on quarteryear on year
- Non Cash Royalty Revenue Related To Sale Of Future Royalties$10.9M$10.9MQoQ -5.5%year on year +3.8%-5.5%+3.8%
- License Collaboration And Other--QoQ -year on year ---